Indian stocks: Visit www.stage2stocks.com →

AbCellera Biologics Inc.

Stage 2 · Advancing · week 21

As of Oct 22, 2026, AbCellera Biologics is in Stage 2, the uptrend phase, now in week 21 (since Jun 1, 2026). It closed at $11.37, 23.3% below its 52-week high and above its 200-day average, which is rising.

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. More about the company

$11.37
-8.67% today
$3.7B · Mid cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is ABCL early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 17w
S4 34w
S2 20w
S4 15w
S2 21w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 1w → S4 17w → S1 11w → S4 34w → S1 13w → S2 4w → S3 3w → S4 10w → S1 3w → S2 20w → S3 7w → S4 15w → S1 5w → S2 21w current
Total tracked: 165 weeks across 14 stage runs.

ABCL among Biotechnology42nd of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…42ABCLStage 2 · wk 2195−7.6%
vs 52W High
-23.3%
$2.78 lo$14.82 hi
23.3% below 52W high, deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 21
1w13w26w
Week 21, proven structure
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
72.2%
200 DMA: $6.60 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.72x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
Short-term trend rising gently
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-7.6%
3M
+114.1%
6M
+180.7%
YTD
+231.5%
1Y
+103.8%
Scan Membership
Breakout Watch
Latest: 2025-02-06
3 appearances in last 60 days. First seen: 2022-08-17.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 21 · Vol 0.72x
2026-10-21S2
Wk 20 · Vol 0.50x
2026-10-20S2
Wk 20 · Vol 0.61x
2026-10-19S2
Wk 20 · Vol 0.44x
2026-10-16S2
Wk 20 · Vol 0.57x
2026-10-15S2
Wk 20 · Vol 0.80x
2026-10-14S2
Wk 19 · Vol 0.43x
2026-10-13S2
Wk 19 · Vol 0.45x
2026-10-12S2
Wk 19 · Vol 0.80x
2026-10-09S2
Wk 19 · Vol 0.65x
2026-10-08S2
Wk 19 · Vol 1.20x
2026-10-07S2
Wk 18 · Vol 0.70x
Moving averages & range
50 DMA
$12.14
200 DMA
$6.60
52W High
$14.82
52W Low
$2.78
5D Low
$11.37
Resistance levels (recent highs)
20d High
$14.82
60d High
$14.82
120d High
$14.82
250d High
$14.82
Next resistance
+30.3%
to 20d High
ROE
-17.3%
Profit margin -248.8%
Dividend Yield
0.00%
P/B 3.9

AbCellera Biologics: quick answers

What stage is AbCellera Biologics in?

As of Oct 22, 2026, AbCellera Biologics (ABCL) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 1, 2026 and is in week 21. What the four stages mean

Is AbCellera Biologics in an uptrend?

Yes. AbCellera Biologics is in a Stage 2 uptrend. It trades 72.2% above its 200-day average, which is rising.

How far is AbCellera Biologics from its 52-week high?

AbCellera Biologics closed at $11.37 on Oct 22, 2026, 23.3% below its 52-week high of $14.82. Its 52-week low is $2.78.

How has AbCellera Biologics performed over the past year?

As of Oct 22, 2026, AbCellera Biologics is up 103.8% over the past year and up 231.5% so far in 2026.

Which sector and industry is AbCellera Biologics in?

AbCellera Biologics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.